{"id":63133,"date":"2026-04-14T21:30:04","date_gmt":"2026-04-14T13:30:04","guid":{"rendered":"https:\/\/flcube.com\/?p=63133"},"modified":"2026-04-14T21:30:05","modified_gmt":"2026-04-14T13:30:05","slug":"zelgens-jaktinib-hits-primary-endpoint-in-phase-iii-atopic-dermatitis-trial-dual-jak-acvr1-inhibitor-expands-beyond-myelofusion","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63133","title":{"rendered":"Zelgen&#8217;s Jaktinib Hits Primary Endpoint in Phase III Atopic Dermatitis Trial \u2013 Dual JAK\/ACVR1 Inhibitor Expands Beyond Myelofusion"},"content":{"rendered":"\n<p><strong>Suzhou Zelgen Biopharmaceuticals Co., Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688266:SHA\">SHA: 688266<\/a>) announced that its <strong>Phase III clinical trial<\/strong> evaluating <strong>jaktinib<\/strong> in adult patients with moderate-to-severe atopic dermatitis (AD) has met the <strong>primary efficacy endpoint<\/strong>. The dual-acting agent, which inhibits both <strong>Janus kinase (JAK)<\/strong> and <strong>activin receptor type 1 (ACVR1)<\/strong>, was first approved in **May 202atomics for *<em>myelofibrosis<\/em>*.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-milestone\">Clinical Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug<\/strong><\/td><td>Jaktinib \u2013 novel dual inhibitor<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>JAK inhibition + ACVR1 suppression<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Moderate-to-separate atopic dermatitis (AD)<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Phase III primary endpoint achieved<\/td><\/tr><tr><td><strong>Previous Approval<\/strong><\/td><td>May 2025: myelofusion subtypes in China<\/td><\/tr><tr><td><strong>Unique Mechanism<\/strong><\/td><td>ACVR1 inhibition improves iron metabolism &amp; anemia<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-differentiation\">Drug Profile &amp; Differentiation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual-Targeting:<\/strong> Simultaneous inhibition of JAK signaling pathway and ACVR1 activity<\/li>\n\n\n\n<li><strong>Anemia Benefit:<\/strong> ACVR1 suppression specifically addresses iron metabolism imbalances and anemia commonly seen in chronic inflammatory conditions<br>&#8211;<strong>Regulatory Foundation:<\/strong> Already approved in China for intermediate\/high-risk primary myelofusion (PMF), polycythemia vera-associated MF (PPV-MF), and essential thrombocythemia-associated MF (PET-Matric fusion)<br>&#8211;<strong>Safety Advantage:<\/strong> Potential for improved safety profile through selective targeting compared to pan-JAK inhibitors<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-implications\">Commercial Implications<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-atopic-dermatitis-market-opportunity\">Atopic Dermatitis Market Opportunity<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global AD Market:<\/strong> Projected $12 billion by 2030 with premium pricing for oral agents<br>&#8211;<strong>China AD Patient Population:<\/strong> Estimated 15 million adults with moderate-to-severe disease<br>&#8211;<strong>Competitive Landscape:<\/strong> Positioned against existing JAK inhibitors with potential differentiation through ACVR1 mechanism<br>&#8211;<strong>Pricing Power:<\/strong> Dual indication strategy enables value-based pricing across multiple therapeutic areas<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-strategic-advantages\">Strategic Advantages<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing Leverage:<\/strong> Existing commercial supply chain from myelofusion approval<br>&#8211;<strong>Regulatory Pathway:<\/strong> Streamlined regulatory process based on established safety database<br>&#8211;<strong>Market Access:<\/strong> Early entry into China&#8217;s growing AD treatment market<br>&#8211;<strong>Pipeline Validation:<\/strong> Success validates Zelgen&#8217;s dual-targeting approach for other pipeline candidates<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-roadmap\">Development Roadmap<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Immediate Next Steps:<\/strong> Complete full data analysis and prepare regulatory submissions<br>&#8211;<strong>Timeline Expectations:<\/strong> Potential NDA submission Q3 2026 with accelerated review possible given unmet need<br>&#8211;<strong>Global Strategy:<\/strong> Consider international partnerships following Chinese approval<br>&#8211;<strong>Additional Indications:<\/strong> Evaluate jaktinib in other inflammatory conditions with anemia comorbidity<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-impact\">Financial Impact<\/h2>\n\n\n\n<p>The successful Phase III readout represents a significant de-risking event for Zelgen&#8217;s pipeline. With myelofusion sales already generating revenue, the AD indication could meaningfully expand total addressable market and support premium valuation.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding development timelines, regulatory pathways, and commercial expectations for jaktinib. Actual results may differ due to risks inherent in pharmaceutical development including regulatory decisions, competitive dynamics, and market acceptance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688266_20260414_VXJX.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688266_20260414_VXJX.\"><\/object><a id=\"wp-block-file--media-60ac60fa-12d0-48a9-a575-2fcf89912181\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688266_20260414_VXJX.pdf\">688266_20260414_VXJX<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688266_20260414_VXJX.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-60ac60fa-12d0-48a9-a575-2fcf89912181\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that its Phase III clinical trial evaluating&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,17,905,246],"class_list":["post-63133","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-auto-immune","tag-clinical-trial-results","tag-sha-688266","tag-zelgen-biopharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Zelgen&#039;s Jaktinib Hits Primary Endpoint in Phase III Atopic Dermatitis Trial \u2013 Dual JAK\/ACVR1 Inhibitor Expands Beyond Myelofusion - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that its Phase III clinical trial evaluating jaktinib in adult patients with moderate-to-severe atopic dermatitis (AD) has met the primary efficacy endpoint. The dual-acting agent, which inhibits both Janus kinase (JAK) and activin receptor type 1 (ACVR1), was first approved in **May 202atomics for *myelofibrosis*.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63133\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zelgen&#039;s Jaktinib Hits Primary Endpoint in Phase III Atopic Dermatitis Trial \u2013 Dual JAK\/ACVR1 Inhibitor Expands Beyond Myelofusion\" \/>\n<meta property=\"og:description\" content=\"Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that its Phase III clinical trial evaluating jaktinib in adult patients with moderate-to-severe atopic dermatitis (AD) has met the primary efficacy endpoint. The dual-acting agent, which inhibits both Janus kinase (JAK) and activin receptor type 1 (ACVR1), was first approved in **May 202atomics for *myelofibrosis*.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63133\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-14T13:30:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-14T13:30:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63133#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63133\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zelgen&#8217;s Jaktinib Hits Primary Endpoint in Phase III Atopic Dermatitis Trial \u2013 Dual JAK\\\/ACVR1 Inhibitor Expands Beyond Myelofusion\",\"datePublished\":\"2026-04-14T13:30:04+00:00\",\"dateModified\":\"2026-04-14T13:30:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63133\"},\"wordCount\":388,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"Clinical trial results\",\"SHA: 688266\",\"Zelgen Biopharmaceuticals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63133#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63133\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63133\",\"name\":\"Zelgen's Jaktinib Hits Primary Endpoint in Phase III Atopic Dermatitis Trial \u2013 Dual JAK\\\/ACVR1 Inhibitor Expands Beyond Myelofusion - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-14T13:30:04+00:00\",\"dateModified\":\"2026-04-14T13:30:05+00:00\",\"description\":\"Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that its Phase III clinical trial evaluating jaktinib in adult patients with moderate-to-severe atopic dermatitis (AD) has met the primary efficacy endpoint. The dual-acting agent, which inhibits both Janus kinase (JAK) and activin receptor type 1 (ACVR1), was first approved in **May 202atomics for *myelofibrosis*.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63133#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63133\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63133#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zelgen&#8217;s Jaktinib Hits Primary Endpoint in Phase III Atopic Dermatitis Trial \u2013 Dual JAK\\\/ACVR1 Inhibitor Expands Beyond Myelofusion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zelgen's Jaktinib Hits Primary Endpoint in Phase III Atopic Dermatitis Trial \u2013 Dual JAK\/ACVR1 Inhibitor Expands Beyond Myelofusion - Insight, China&#039;s Pharmaceutical Industry","description":"Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that its Phase III clinical trial evaluating jaktinib in adult patients with moderate-to-severe atopic dermatitis (AD) has met the primary efficacy endpoint. The dual-acting agent, which inhibits both Janus kinase (JAK) and activin receptor type 1 (ACVR1), was first approved in **May 202atomics for *myelofibrosis*.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63133","og_locale":"en_US","og_type":"article","og_title":"Zelgen's Jaktinib Hits Primary Endpoint in Phase III Atopic Dermatitis Trial \u2013 Dual JAK\/ACVR1 Inhibitor Expands Beyond Myelofusion","og_description":"Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that its Phase III clinical trial evaluating jaktinib in adult patients with moderate-to-severe atopic dermatitis (AD) has met the primary efficacy endpoint. The dual-acting agent, which inhibits both Janus kinase (JAK) and activin receptor type 1 (ACVR1), was first approved in **May 202atomics for *myelofibrosis*.","og_url":"https:\/\/flcube.com\/?p=63133","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-14T13:30:04+00:00","article_modified_time":"2026-04-14T13:30:05+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63133#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63133"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zelgen&#8217;s Jaktinib Hits Primary Endpoint in Phase III Atopic Dermatitis Trial \u2013 Dual JAK\/ACVR1 Inhibitor Expands Beyond Myelofusion","datePublished":"2026-04-14T13:30:04+00:00","dateModified":"2026-04-14T13:30:05+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63133"},"wordCount":388,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","Clinical trial results","SHA: 688266","Zelgen Biopharmaceuticals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63133#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63133","url":"https:\/\/flcube.com\/?p=63133","name":"Zelgen's Jaktinib Hits Primary Endpoint in Phase III Atopic Dermatitis Trial \u2013 Dual JAK\/ACVR1 Inhibitor Expands Beyond Myelofusion - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-14T13:30:04+00:00","dateModified":"2026-04-14T13:30:05+00:00","description":"Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that its Phase III clinical trial evaluating jaktinib in adult patients with moderate-to-severe atopic dermatitis (AD) has met the primary efficacy endpoint. The dual-acting agent, which inhibits both Janus kinase (JAK) and activin receptor type 1 (ACVR1), was first approved in **May 202atomics for *myelofibrosis*.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63133#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63133"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63133#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zelgen&#8217;s Jaktinib Hits Primary Endpoint in Phase III Atopic Dermatitis Trial \u2013 Dual JAK\/ACVR1 Inhibitor Expands Beyond Myelofusion"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63133","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63133"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63133\/revisions"}],"predecessor-version":[{"id":63136,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63133\/revisions\/63136"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63133"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63133"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63133"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}